Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14680363 | 0.80 | SMN1; SMN2 (0.47) | MAPTKMT2AHPGDTSHRALDH1A1 | |
| SCHEMBL7285310 | 0.80 | HTT (0.48) | MAPTMEN1KMT2AHPGDTSHR | |
| SCHEMBL4518269 | 0.79 | PTGS1 (0.48) | MAPTLMNAMEN1KMT2AHPGD | |
| SCHEMBL4452624 | 0.79 | MGLL (0.40) | LMNAMEN1KMT2AHPGDTSHR | |
| SCHEMBL4805409 | 0.78 | GAA (0.63) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1095516 | 0.77 | MEN1 (0.64) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL6358441 | 0.77 | MAPT (0.60) | MAPTLMNAMEN1KMT2AHPGD | |
| SCHEMBL29812845 | 0.77 | MEN1 (0.64) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL11038736 | 0.75 | TSHR (0.53) | MAPTLMNAKMT2ATSHRALDH1A1 | |
| SCHEMBL21711263 | 0.75 | RAB9A (0.40) | MAPTLMNAMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481574-B2 | (2Z)-2-(3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene)-1-(5-chloro-2-methoxyphenyl)ethanone; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2013-07-09 | — | — | US | disclosed |
| US-20080255123-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008063781-A2 | CHEMICAL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255123-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | MAPT 1588/4885LMNA 2187/4885MEN1 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.